May 8, 2023 11:17 AM EDT
Startups
Cell/Gene Tx

CRISPR uni­corn Mam­moth backs off di­ag­nos­tics re­search, lay­ing off 35 on test­ing team to fo­cus on ther­a­peu­tics

Andrew Dunn

Senior Biopharma Correspondent

Mam­moth Bio­sciences is tak­ing a big step away from its orig­i­nal am­bi­tion of up­end­ing the di­ag­nos­tics busi­ness with CRISPR, and has laid off the bulk …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times